Cargando…

BRCA1 and BRCA2 deficient tumour models generate distinct ovarian tumour microenvironments and differential responses to therapy

Clinical trials are currently exploring combinations of PARP inhibitors and immunotherapies for the treatment of ovarian cancer, but their effects on the ovarian tumour microenvironment (TME) remain unclear. Here, we investigate how olaparib, PD-L1 monoclonal antibodies, and their combination can in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Farokhi Boroujeni, Salar, Rodriguez, Galaxia, Galpin, Kristianne, Yakubovich, Edward, Murshed, Humaira, Ibrahim, Dalia, Asif, Sara, Vanderhyden, Barbara C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10683289/ https://www.ncbi.nlm.nih.gov/pubmed/38017453 http://dx.doi.org/10.1186/s13048-023-01313-z

Ejemplares similares

The Tumor Microenvironment of Epithelial Ovarian Cancer and Its Influence on Response to Immunotherapy
por: Rodriguez, Galaxia M., et al.
Publicado: (2018)

Ovarian Cancer Immunotherapy: Preclinical Models and Emerging Therapeutics
por: McCloskey, Curtis W., et al.
Publicado: (2018)

The Tumor Immune Profile of Murine Ovarian Cancer Models: An Essential Tool for Ovarian Cancer Immunotherapy Research
por: Rodriguez, Galaxia M., et al.
Publicado: (2022)

LY75 Suppression in Mesenchymal Epithelial Ovarian Cancer Cells Generates a Stable Hybrid EOC Cellular Phenotype, Associated with Enhanced Tumor Initiation, Spreading and Resistance to Treatment in Orthotopic Xenograft Mouse Model
por: Mehdi, Sadia, et al.
Publicado: (2020)

Genome-Wide Gene Expression Analyses of BRCA1- and BRCA2-Associated Breast and Ovarian Tumours
por: Wiggins, George A. R., et al.
Publicado: (2020)

Practice guidelines for BRCA1/2 tumour testing in ovarian cancer
por: Grafodatskaya, Daria, et al.
Publicado: (2022)

Anti‐tumoural activity of the G‐quadruplex ligand pyridostatin against BRCA1/2‐deficient tumours
por: Groelly, Florian J, et al.
Publicado: (2022)

Characterization of BRCA Deficiency in Ovarian Cancer
por: Barbero, Giovanna, et al.
Publicado: (2023)

Management of BRCA Tumour Testing in an Integrated Molecular Tumour Board Multidisciplinary Model
por: Azzollini, Jacopo, et al.
Publicado: (2022)

Comparative analysis of syngeneic mouse models of high-grade serous ovarian cancer
por: Cook, David P., et al.
Publicado: (2023)

Clues to the Function of the Tumour Susceptibility Gene BRCA2
por: Gayther, Simon A., et al.
Publicado: (1998)

Chlorambucil targets BRCA1/2‐deficient tumours and counteracts PARP inhibitor resistance
por: Tacconi, Eliana MC, et al.
Publicado: (2019)

Sox11 regulates mammary tumour-initiating and metastatic capacity in Brca1-deficient mouse mammary tumour cells
por: Tsang, Siu Man, et al.
Publicado: (2021)

Resveratrol increases BRCA1 and BRCA2 mRNA expression in breast tumour cell lines
por: Fustier, P, et al.
Publicado: (2003)

Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families
por: Eerola, Hannaleena, et al.
Publicado: (2005)

Reflex BRCA1 and BRCA2 tumour genetic testing for high-grade serous ovarian cancer: streamlined for clinicians but what do patients think?
por: McCuaig, Jeanna M., et al.
Publicado: (2022)

Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families
por: Eerola, Hannaleena, et al.
Publicado: (2008)

A novel tumour-based test to identify breast cancer due to BRCA1 and BRCA2 mutations
por: An, Q, et al.
Publicado: (2010)

Breast Cancers with Ocular Metastases are Early Onset, Non-Familial and Non-BRCA1/BRCA2 Tumours
por: Królewska, Katarzyna, et al.
Publicado: (2004)

Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes
por: Stefansson, Olafur Andri, et al.
Publicado: (2009)

Microarray based expression profiling of BRCA1 mutated human tumours using a breast-specific platform to identify a profile of BRCA1 deficiency
por: Lamers, E, et al.
Publicado: (2010)

BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case–control study
por: Bjørge, T, et al.
Publicado: (2004)

Biallelic BRCA Loss and Homologous Recombination Deficiency in Nonbreast/Ovarian Tumors in Germline BRCA1/2 Carriers
por: Wineland, Dylane, et al.
Publicado: (2023)

Correction: Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes
por: Stefansson, Olafur Andri, et al.
Publicado: (2009)

Tumour spectrum in non-BRCA hereditary breast cancer families in Sweden
por: Wendt, Camilla, et al.
Publicado: (2015)

Frequent somatic loss of BRCA1 in breast tumours from BRCA2 germ-line mutation carriers and vice versa
por: Staff, S, et al.
Publicado: (2001)

Relationship of patients' age to histopathological features of breast tumours in BRCA1 and BRCA2 and mutation-negative breast cancer families
por: Eerola, Hannaleena, et al.
Publicado: (2005)

Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2
por: Mulligan, Anna Marie, et al.
Publicado: (2011)

BRCA immunohistochemistry for screening of BRCA mutation in epithelial ovarian cancer patients
por: Manchana, Tarinee, et al.
Publicado: (2020)

The Impact of BRCA1- and BRCA2 Mutations on Ovarian Reserve Status
por: C.E, Drechsel Katja, et al.
Publicado: (2022)

Tumour Versus Germline BRCA Testing in Ovarian Cancer: A Single-Site Institution Experience in the United Kingdom
por: Akaev, Iolia, et al.
Publicado: (2021)

CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours
por: Xu, Hong, et al.
Publicado: (2017)

Sirtuin inhibition is synthetic lethal with BRCA1 or BRCA2 deficiency
por: Bajrami, Ilirjana, et al.
Publicado: (2021)

Distinct functions of BRCA1 and BRCA2 in double-strand break repair
por: Liu, Yilun, et al.
Publicado: (2002)

Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer
por: Lee, Chee Khoon, et al.
Publicado: (2019)

Tumour Suppressor Mechanisms in the Control of Chromosome Stability: Insights from BRCA2
por: Venkitaraman, Ashok R.
Publicado: (2014)

BRCA2 carriers with male breast cancer show elevated tumour methylation
por: Deb, Siddhartha, et al.
Publicado: (2017)

A commentary on the discrepancy between blood and tumour BRCA testing: An open question
por: De Paolis, Elisa, et al.
Publicado: (2022)

Transcriptome Patterns of BRCA1- and BRCA2- Mutated Breast and Ovarian Cancers
por: Arakelyan, Arsen, et al.
Publicado: (2021)

Prevalence of BRCA homopolymeric indels in an ION Torrent-based tumour-to-germline testing workflow in high-grade ovarian carcinoma
por: Azzollini, Jacopo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_nperebti2km8oiehorc68ai5rh